5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas
Background: Neuroendocrine carcinomas (NECs) are classified by the World Health Organization as poorly differentiated, aggressive Grade 3 tumors with high proliferative indices and frequent lung involvement. While initial treatment for advanced NEC typically involves etoposide and platinum-based the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841549949073883136 |
|---|---|
| author | I-Wei Ho Nai-Jung Chiang Jiun-I Lai Peter Mu-Hsin Chang San-Chi Chen Yi-Ping Hung Ming-Huang Chen |
| author_facet | I-Wei Ho Nai-Jung Chiang Jiun-I Lai Peter Mu-Hsin Chang San-Chi Chen Yi-Ping Hung Ming-Huang Chen |
| author_sort | I-Wei Ho |
| collection | DOAJ |
| description | Background:
Neuroendocrine carcinomas (NECs) are classified by the World Health Organization as poorly differentiated, aggressive Grade 3 tumors with high proliferative indices and frequent lung involvement. While initial treatment for advanced NEC typically involves etoposide and platinum-based therapies, standardized options for subsequent lines of treatment are lacking. This study evaluates the efficacy and outcomes of various second-line treatments for NECs following progression after initial therapy.
Materials and Methods:
A retrospective cohort study was conducted at Taipei Veterans General Hospital, Taiwan, from January 2016 to June 2023. The study included patients aged 18 years or older diagnosed with extrapulmonary NEC who had progressed following initial platinum and etoposide therapy. Treatment response and survival outcomes were assessed.
Results:
The study analyzed 34 patients across four treatment regimens: 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI), 5-fluorouracil, leucovorin, and irinotecan, 5-fluorouracil, leucovorin, and Nivolumab + Ipilimumab. The FOLFOXIRI regimen demonstrated the highest objective response rate of 33.3% and a disease control rate of 66.7%, compared to the other groups, with a median progression-free survival of 4.1 months and median overall survival of 9.7 months.
Conclusion:
The FOLFOXIRI regimen shows potential as an effective second-line treatment for patients with extrapulmonary NEC who have progressed after first-line therapy with platinum/etoposide. |
| format | Article |
| id | doaj-art-b178346253064d419df3f80eb4e625d4 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-b178346253064d419df3f80eb4e625d42025-01-10T12:26:08ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062024-12-0111413414010.4103/ejcrp.eJCRP-D-24-000325-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine CarcinomasI-Wei HoNai-Jung ChiangJiun-I LaiPeter Mu-Hsin ChangSan-Chi ChenYi-Ping HungMing-Huang ChenBackground: Neuroendocrine carcinomas (NECs) are classified by the World Health Organization as poorly differentiated, aggressive Grade 3 tumors with high proliferative indices and frequent lung involvement. While initial treatment for advanced NEC typically involves etoposide and platinum-based therapies, standardized options for subsequent lines of treatment are lacking. This study evaluates the efficacy and outcomes of various second-line treatments for NECs following progression after initial therapy. Materials and Methods: A retrospective cohort study was conducted at Taipei Veterans General Hospital, Taiwan, from January 2016 to June 2023. The study included patients aged 18 years or older diagnosed with extrapulmonary NEC who had progressed following initial platinum and etoposide therapy. Treatment response and survival outcomes were assessed. Results: The study analyzed 34 patients across four treatment regimens: 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI), 5-fluorouracil, leucovorin, and irinotecan, 5-fluorouracil, leucovorin, and Nivolumab + Ipilimumab. The FOLFOXIRI regimen demonstrated the highest objective response rate of 33.3% and a disease control rate of 66.7%, compared to the other groups, with a median progression-free survival of 4.1 months and median overall survival of 9.7 months. Conclusion: The FOLFOXIRI regimen shows potential as an effective second-line treatment for patients with extrapulmonary NEC who have progressed after first-line therapy with platinum/etoposide.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00032extrapulmonary5-fluorouracilleucovorinand irinotecan5-fluorouracilleucovorinoxaliplatinand irinotecansecond-line therapyipilimumabneuroendocrine carcinoma5-fluorouracilleucovorinneuroendocrine carcinomasnivolumab |
| spellingShingle | I-Wei Ho Nai-Jung Chiang Jiun-I Lai Peter Mu-Hsin Chang San-Chi Chen Yi-Ping Hung Ming-Huang Chen 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas Journal of Cancer Research and Practice extrapulmonary 5-fluorouracil leucovorin and irinotecan 5-fluorouracil leucovorin oxaliplatin and irinotecan second-line therapy ipilimumab neuroendocrine carcinoma 5-fluorouracil leucovorin neuroendocrine carcinomas nivolumab |
| title | 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas |
| title_full | 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas |
| title_fullStr | 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas |
| title_full_unstemmed | 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas |
| title_short | 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas |
| title_sort | 5 fluorouracil leucovorin oxaliplatin and irinotecan as a potential standard for second line therapy in extrapulmonary neuroendocrine carcinomas |
| topic | extrapulmonary 5-fluorouracil leucovorin and irinotecan 5-fluorouracil leucovorin oxaliplatin and irinotecan second-line therapy ipilimumab neuroendocrine carcinoma 5-fluorouracil leucovorin neuroendocrine carcinomas nivolumab |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00032 |
| work_keys_str_mv | AT iweiho 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT naijungchiang 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT jiunilai 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT petermuhsinchang 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT sanchichen 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT yipinghung 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas AT minghuangchen 5fluorouracilleucovorinoxaliplatinandirinotecanasapotentialstandardforsecondlinetherapyinextrapulmonaryneuroendocrinecarcinomas |